Abstract: Neuroblastoma is one of the most common and aggressive types of pediatric cancers, making up about 7% of all childhood cancers. Neuroblastoma arises from the failure of neural crest cell precursors to differentiate, and inducing cell differentiation is one of the most important treatment approaches for neuroblastoma. MicroRNAs regulate gene expression by performing post-transcriptional gene modification by mainly translational suppression and mRNA degradation. The dysregulation of these molecules has been shown to be related to tumor development, tumor metastasis and drug resistance, and the promise of developing microRNA-based therapeutics for cancers has been demonstrated. Many recent studies have also provided evidence for the involvement of microRNAs in differentiation of neuroblastoma cells, suggesting the potential of developing microRNA-based differentiation therapies for neuroblastoma. Here we review the recent findings on the role of microRNAs in regulating cell differentiation, with a main focus on neuroblastoma cells. The investigations on the therapeutic potential of microRNAs in neuroblastoma therapy and differentiation therapy are also reviewed. 
Introduction
Neuroblastoma is one the most common and aggressive extracranial cancers in children [1] . Neuroblastoma makes up about 7% of all childhood cancers, with 700 new cases in the USA every year in children under the age of 15 [1] . Approximately 60% of the cases diagnosed have neuroblastoma already spread to the lymph nodes, where children with this disease typically do not live past 10 years of age [1] [2] [3] . Neuroblastoma is a neoplasm of the sympathetic nervous system, arising from the failure of neural crest cell precursors to differentiate; this disruption of the differentiation process allows for a predisposition of the neural crest precursors to transform into malignant cells [1, 4] .
Anti-cancer drugs of diverse therapeutic mechanisms, including differentiation-inducing agents, angiogenesis inhibitors, inhibitors of oncogenic tyrosine kinases, histone deacetylase inhibitors and demethylating agents, have been used to treat neuroblastoma [5] [6] [7] . Since loss of cell differentiation has a crucial role in neuroblastoma tumorigenesis, differentiation therapy plays an important role in treating neuroblastoma and has been proven to be effective in preventing recurrence in a portion of the neuroblastoma cases [4, 8, 9] . Retinoids provide the most potent differentiation induction for neuroblastoma and have been used as standard-of-care treatment for post-remission maintenance therapy in high-risk neuroblastoma [4, 8, 9] , However, more than 50% of the retinoic acid-treated patients developed recurrence, suggesting resistance to retinoid acids and the need to develop new differentiation therapies for these resistant neuroblastomas. microRNAs (miRNAs) have been demonstrated to play key roles in controlling cell differentiation, 214 doi:10.18282/amor.v3.i5.233 tissue development and tumorigenesis [10] [11] [12] [13] [14] . The role of miRNAs in neuroblastoma tumorigenesis has also been intensively investigated and multiple miRNAs that show strong functionality in modulating neuroblastoma cell differentiation have been identified. This suggests the potential to develop miRNA-based differentiation therapy for neuroblastoma. Here, we review the research findings on the role of miRNAs in neuroblastoma tumorigenesis and recent progress towards miRNA-based therapeutics with a focus on the role of miRNAs in neuroblastoma cell differentiation and their potential in neuroblastoma differentiation therapy.
The diverse role of miRNAs in neuroblastoma tumorigenesis
miRNAs are endogenously expressed 20-25 nucleotidelong non-coding RNAs that regulate transcription and the expression of many genes within the cell. They function by binding to the 3' UTR or 5' UTR of a targeted mRNA by complementary base pairing, such that post-transcriptional regulation of gene expression may occur through translational suppression or mRNA degradation [15, 16] .
Aberrant expressions of miRNAs, along with over-and under-expression of many target genes of these miRNAs, have been linked to neuroblastoma pathogenesis [17] [18] [19] .
Some of the first miRNAs that have been related to neuroblastoma pathogenesis include miR-15 and miR-16 [20] . These two miRNAs target tumor suppressor gene BCL2 that encodes an apoptosis-regulating protein, B-cell lymphoma 2 (Bcl-2) [20] . The inactivation of these miRNAs has been suggested to contribute to the tumorigenesis and progression of neuroblastoma [20] . More recently, miRNAs that have potent differentiation-inducing functions in neuroblastoma, such as miR-124-3p, miR-506-3p, miR449a and miR-34a, have been identified [21] . The strong function of miRNAs in modulating neuroblastoma cell differentiation suggests that miRNAs are involved in the early stage of the neuroblastoma tumorigenesis pathways. miRNAs have been also indicated to be involved in the invasion and metastasis of neuroblastoma. For example, miR-10b, miR-29a/b and miR-335, which are known to promote metastasis, are found to be up-regulated in metastatic neuroblastoma tumors relative to non-metastatic tumors; whereas miR-338, miR-7 and the Let-7 family, which are known to have anti-metastatic roles, are found to be down-regulated in metastatic neuroblastoma tumors [22] .
Recently, miR-21 have been related to chemoresistance in neuroblastoma, suggesting miRNAs may also play an important role in determining the resistance of cancers to chemotherapies [15, 23] . The involvement of miRNAs in these diverse aspects of neuroblastoma pathogenesis strongly suggests their diagnostic and therapeutic values in neuroblastoma.
miRNAs in neuroblastoma diagnosis and therapy
As miRNAs have been demonstrated to play a role in diverse aspects of neuroblastoma pathogenesis, including differentiation, metastasis and chemoresistance, miRNAs have been intensively studied for their potential as diagnostic and prognostic markers, as well as targets for neuroblastoma therapy. For example, Chen et al. performed a miRNA profiling study in 157 primary neuroblastoma tumors and found that the differential expression of 32 miRNAs was correlated with patient prognosis, tumor cell differentiation and apoptosis, suggesting the potential diagnostic values of these miRNAs [24] . In another study, next-generation sequencing was applied to determine differentially expressed miRNAs in neuroblastoma cells isolated from primary tumors at diagnosis and at relapse after intensive treatments [25] . It was observed that 8 miRNAs were upregulated, while 34 were downregulated after treatment [25] . Ingenuity Pathway Analysis (IPA) was then used to predict the possible target genes of these differentially expressed miRNAs, and many of these target genes were found to be associated with cancer progression and drug resistance, suggesting that these miRNAs may be used as possible neuroblastoma biomarkers to predict drug response and patient prognosis [25] .
Approaches have been explored to target tumorigenesisassociated miRNAs for the treatment of various types of cancers, including neuroblastoma [26] [27] [28] [29] [30] [31] . One of most promising strategies is to use miRNA mimics, consisting of partially double-stranded RNAs that are designed to mimic the function of endogenous miRNAs and, thereby, increase the functional miRNA levels in the cells, comparable to the overexpression of tumor-suppressive miRNAs to treat cancer [32] [33] [34] [35] [36] [37] . In neuroblastoma, since many miRNAs that have potent differentiation-inducing functions have been identified, as reviewed below, this approach can be 215 extended to develop miRNA mimic-based differentiation therapies, as reviewed in the final section at the end of this article.
miRNAs in neuroblastoma cell differentiation
The role of miRNAs in modulating neuroblastoma cell differentiation has been investigated in many studies using diverse experimental approaches such as miRNA expression profiling in differentiated and undifferentiated neuroblastoma cells, and by examining the effect of reducing or increasing miRNA expression on cell differentiation both in vitro and in vivo neuroblastoma models. Together, these studies have helped to solidify the strong differentiation-inducing functionality of these miRNAs. In the sections below, we review each of these [54, 55] miR-18a ESR1 Promote [65] miR-34a Undetermined Promote [21] miR-125a/b TRKc Promote [57, 61] miR-449a MFAP4, PKP4, TSEN15 Promote [51] miR-338-3p AATK Promote [66] miR-506-3p CDK4, STAT3 Promote miRNAs and their influence on neuroblastoma growth and differentiation. At the end, we have also reviewed a group of miRNAs that have been suggested to have differentiation-regulating function by limited studies; these miRNAs need to be further investigated in future studies. Table 1 and Figure 1 provide a summary of the research findings on miRNAs that regulate neuroblastoma cell differentiation and their target genes that mediate their differentiation-regulating functions.
miRNA-506-3p and miRNA-124-3p
High-content screening approaches (HCS), which are based on the detection of neurite outgrowth as a morphological marker of neuroblastoma cell differentiation, have been developed to discover new differentiation-inducing agents [9, 21, 38, 39] . By combining the HCS technique and a library of miRNA mimics, our group has identified 14 miRNAs that induce neuroblastoma cell differentiation [21] .
Two miRNAs that share the same seed sequence, miR-506-3p and miR-124-3p, are identified as the most potent differentiation-inducing miRNAs [21] .
Consistent with our findings, the function of miR-124 in neuronal cell differentiation and neural tissue development has been established in previous studies. Åkerblom et al. investigated the function of miR-124 in vivo [40] . This study showed that the neurogenesis was blocked when the expression of miR-124 was inhibited [40] . A study performed by Zou et al. examined the effects of overexpression of miR-124 on cell differentiation in vitro in rat neural stem cells and in vivo in cortical neurons [41] . Upon transfection of miR-124 with a lentiviral vector into bone marrowderived mesenchymal stem cells, an increase in neuronal cell differentiation markers β (III) tubulin and tubulinassociated protein 2 were observed [41] . After the miR-124-transfected stem cells were transplanted into the rat spinal cord, a large number of cells positive for the neuronal marker neurofilament-200 were observed in the transplanted region, confirming the role of miR-124 in inducing neuronal cell differentiation [41] . Mondanizadeh et al. further investigated the mechanisms by which miR-124 induces neuronal cell differentiation [42] . They found that SP1, the gene that encodes the transcription factor Sp1 protein, is a direct target of miR-124 and its down-regulation plays an important role in mediating the differentiationinducing function of miR-124 [42] . These studies altogether demonstrated the critical role of miR-124 in normal neural cell differentiation and neural tissue development.
The differentiation-inducing function of miR-124 has also been investigated in cancers including neuroblastoma. Makeyev et al. investigated the miR-124 targets that mediate its differentiation function by overexpressing miR-124 in neuroblastoma cells in vitro [43] . It was determined that PTBP1, a splicing repressor that is known to play a role in cell differentiation during nervous system development, is a direct target of miR-124 and has a role in the differentiation-inducing function of miR-124 in neuroblastoma [43] [44] [45] . miR-124 has also been implicated as an important miRNA involved in the cell differentiation of cancers of non-neuronal origin as well; this study, done by Dong et al., used over 130 breast cancer patients to examine the tissue expression levels of this miRNA [46] . It was found that there was significant correlation between low miR-124 expression and poor pathological differentiation and poorer patient prognosis, suggesting a possible role of miR-124 in determining breast cancer cell differentiation [46] .
The differentiation-inducing function of miR-506-3p was first discovered in our group from the HCS [21] . miR-506-3p shares the same seed sequence with miR-124-3p [21] . Further mechanistic investigation shows that two of its direct targets, CDK4 and STAT3, play a role in mediating its differentiation-inducing function of both miR-506-3p and miR-124-3p [21] . The clinical relevance of miR-506-3p expression in neuroblastoma tumorigenesis needs to be further investigated in the future.
miRNA-34a
miRNA-34a was first observed to be overexpressed in unfavorable tumors of neuroblastoma patients [47] . Following this observation, welch et al. further examined the function of this miRNA by overexpressing miR-34a in neuroblastoma cells in vitro, and they detected a sharp reduction in cell proliferation in miR-34a overexpressed cells, suggesting its tumor suppressive function in neuroblastoma [47] [48] [49] . It was first determined that its direct target gene, E2F3, plays a role in mediating its cell growth-suppressive function in neuroblastoma cells [47] .
miR-34a (i.e., miR-34a-5p) was among the group of differentiation-inducing miRNAs that we identified through HCS [21] . Several other studies also have demonstrated the differentiation-inducing function of miR-34a, suggesting
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that inducing cell differentiation may play a key role in the tumor suppressive function of miR-34a [50] . The study performed by Aranha et al. observed cell differentiation in mouse neural stem cells following the overexpression of miR-34a [50] . The study done by Agostini et al. also showed the importance of this miRNA in neuronal development [48] . In the more recent study performed by Yu et al., miR-34a was shown to induce smooth muscle cell (SMC) differentiation from pluripotent stem cells, which is mediated by the upregulating expression of its target deacetylase sirtuin 1 (SirT1) [49] . Overall, current studies clearly show that miR-34a functions as differentiation inducer not only in neural cells, but may also play a role in modulating differentiation of other cell types.
miRNA-449a
The differentiation-inducing function of miR-449a was first identified from the HCS in our group and was further characterized in our group in multiple neuroblastoma cell lines with different genetic backgrounds [21, 51] . Our study further showed that miR-449a suppresses neuroblastoma cell proliferation by two mechanisms: inducing cell differentiation by directly down-regulating expression of its target genes MFAP4, PKP4 and TSeN15, and inducing cell cycle arrest by directly down-regulating expression of its target genes CDK4 and LEF1 [51] . miR-449a has been found to induce differentiation of other cell types. Liu et al. ectopically expressed miR-449a in vitro in pluripotent cells, and detected osteoblast differentiation markers after several days [52] . The differentiation of these cells was correlated with the down-regulation of HDAC1, a direct target of miR-449a [52] . A study done by Capuano et al. suggested that miR-449a may also be involved in the differentiation of intestinal cells [53] . These results together provide evidence for the function of miR-449a as a potent inducer of cell differentiation in multiple types of cells including neuroblastoma cells.
miRNA-10a/b
In 2011, Stallings et al. examined the expression levels of miRNAs in several neuroblastoma cell lines treated with all-trans retinoic acid (ATRA) in vitro [54] . The study aimed to determine miRNAs involved in neuroblastoma differentiation [54] . miR-10a/b was found to be significantly overexpressed in ATRA-treated and -differentiated neuroblastoma cells. Nuclear receptor corepressor 2 (NCOR2) was identified as a downregulated target of miR10a/b [54] . The knockdown of NCOR2 was observed to not only induce neurite outgrowth, but also downregulate MYCN [54] . In another study, miR-10a/b contributed to retinoic acid-induced neuroblastoma cell differentiation via targeting SFRS1 [55] . These results indicate the function of miR-10a/b in inducing neuroblastoma cell differentiation, and this function is mediated by down-regulating expression of its targets NCOR2 and SFRS1. In contrast, a study based on osteoblasts showed a decrease in miR10a expression during induced differentiation. In addition, a miR-10a mimic was able to suppress differentiation in mouse osteoblast cells; along with these results, the study concluded that miR-10a inhibits cell differentiation in osteoblasts [56] . These findings together suggest that the function of this miRNA in modulating cell differentiation may be cell context-specific, and its specific function in particular cell types needs to be further evaluated in future studies.
miRNA-125a/b
The expression profile of miRNAs in ATRA-treated neuroblastoma cell line SH-SY5Y was examined in a study performed by Le et al. [57] . After inducing differentiation by ATRA, miR-125b was among the six miRNAs significantly upregulated by ATRA [57] . Functional investigation in this study further showed the role of miR-125b in both spontaneous and induced differentiation of SH-SH5Y cells.
In this study, miR-125b was found to be also upregulated during the differentiation of human neural progenitor ReNcell vM cells in vitro, and miR-125b ectopic expression significantly promoted neurite outgrowth of these cells [57] . These findings altogether support the function of miR-125b in inducing neuronal differentiation. In investigating the mechanism underlying the differentiationinducing function of miR-125b, Laneve et al. found that an iso-form of neurotrophin receptor tropomyosin-related kinase C (TrkC), which has been known to play a critical role in neuronal differentiation, was seen significantly repressed in neuroblastoma cells after the ectopic expression of miR125a/b [58] [59] [60] [61] . The study also examined the expression of miR-125b in primary neuroblastoma tumors and found that this miRNA was down-regulated in primary neuroblastoma tumors, supporting its potential role in neuroblastoma tumorigenesis [61] .
Contradictive results were also observed for miR-125b, which shows that miR-125b functions as an inhibitor of cell differentiation [62] [63] [64] . For example, the overexpression of miR-125b was shown to inhibit the differentiation of mouse embryonic stem cells (eSCs) into endoderm and ectoderm, and also inhibit ATRA-induced neuron development in embryoid bodies in vivo [62] . Another study indicated that overexpression of miR-125b inhibits the differentiation of primary B cells [64] .
Overall, current studies on miR-125a/b show that these miR-125a/b may also be cell type-specific regarding its role in regulating cell differentiation.
Other miRNAs
Besides the above, there are other miRNAs that have been implicated to modulate differentiation of malignant cells in limited studies. miR-18a was shown to be involved in neuroblastoma cell differentiation by Lovén et al. [65] . They further showed that, after lentiviral restoration of its direct target estrogen receptor α (ESR1) in cells overexpressing miR-18a, the neuroblastoma cells were observed to undergo cell cycle arrest and cell differentiation, indicating that the differentiation-inducing function is mediated by down-regulating its direct target ESR1 [65] . miR-338-3p
is another miRNA that has been added to the family of differentiation-regulating miRNAs. Upon overexpression of miR-338-3p in neuroblastoma cells, cell differentiation and down-regulation of its target gene, apoptosis-associated tyrosine kinase (AATK), is observed, suggesting that downregulation of AATK is responsible for the differentiationinducing function of this miRNA [66] . A more recent study performed by Samaraweera et al. observed changes in the miRNA expression profile of differentiation-induced neuronal cells versus undifferentiated cells [67] . Increased expression levels of three miRNAs, including miR-21, miR-221 and miR-335, are associated with non-neuronal phenotype; whereas, increased level of miR-375 are associated with neuroblastic phenotype [67] . MiR-375 is further found to down-regulate the expressions of HAND1 and JAG1, known modulators of neuronal differentiation, further suggesting functional role of miR-375 in regulating neuronal cell differentiation [67] .
Overall, studies in differentiation-regulation function of these miRNAs are limited, and further studies are definitely needed to confirm their functions in regulating cell differentiation including neuroblastoma.
MiRNAs in neuroblastoma differentiation therapy
The therapeutic potential of miRNA-based agents has been investigated in in vivo models of many types of cancers [68] [69] [70] [71] [72] [73] [74] . Systemic delivery methods, such as encapsulation of miRNAs in nanoparticles or chemical modification of miRNAs, could be an effective technique for personalized therapies and cancer treatments [68] . Studies in in vivo neuroblastoma models have also suggested the promise of miRNA-based therapies in treating neuroblastoma [75] . For example, Tivnan et al. performed
an in vivo study in a murine orthotopic xenograft model to determine if a mimic of miR-34a, a tumor suppressive miR34a that have been demonstrated in neuroblastoma [47, 76] , inhibits neuroblastoma tumor growth [77] . This study found that miRNA-34a mimic treatment resulted in a significant decrease in tumor growth, an increase in tumor cell apoptosis and a significant reduction of angiogenesis, suggesting the therapeutic potential of miR-34a mimic in neuroblastoma [77] . A study on the tumor suppressive miR-497 showed that the overexpression of miR-497 reduces tumor growth and inhibits vascular permeabilization in neuroblastoma xenograft model, supporting a potential therapeutic strategy by overexpressing miR-497 [78] .
Based on the above, the connections between miRNAs and neuroblastoma cell differentiation certainly suggest the promise of developing miRNA-based differentiation therapy. However, there are limited in vivo studies specifically focusing on miRNA-based differentiation therapies in neuroblastoma. For example, miR-34a has been found to have a strong differentiation-inducing function [21, [47] [48] [49] [50] ; however, the effect of miR-34 mimic treatment on neuroblastoma differentiation was not investigated in the above study on miR-34a mimic [77] . The study in our group has shown the therapeutic promise of the differentiation-inducing miRNA mimics of miR-506-3p and miR-449a using in vitro approaches [21, 51] ; in vivo therapeutic investigations on these miRNAs certainly need be pursued in the future. 
Conclusion

